-
Why Pharma can’t ignore friendshoring in supply chain
Read more: Why Pharma can’t ignore friendshoring in supply chainBora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.
More in Latest News
In Conversation With
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
AI and Technology
Latest news
-
Evogene and Australian Uni partner to tackle chemotherapy resistance in lung cancer
AI-driven collaboration between the Israeli company and Queensland University of Technology targets cellular pathways to overcome treatment hurdles in non-small cell lung cancer.
Expert Interviews
-
Why Pharma can’t ignore friendshoring in supply chain
Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.
Sustainability In Pharma
Latest news
-
Building sustainable medical products: Polaroid exec on innovation and challenges
Head of Product at Polaroid Therapeutics, Paul Saunders, shares his approach to embedding sustainability in healthcare innovation.
Company Analysis
-
CVS Health makes headway in becoming environmentally sustainable
The progress and trend in the reduction of the GHG emissions and GHG emission intensity over the last six years reflect that CVS Health’s progress towards the goal of Net-zero by 2050 is on track.
Looking to read an in-depth analysis of Sustainability, AI, and the Latest Technology in healthcare sector
You can access members-only exclusive content for as little as $4.2 per month.
More Posts
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
Boehringer picks AI imaging tech as co-primary endpoint for IPF trial
Brainomix’s e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim’s Phase III DROP-FPF study.
-
VCU researchers win $1.8 million US DoD grant for cancer therapy
The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.
-
Becton Dickinson and ten23 partner on wearable injector supply
Partnership will support the supply for Becton, Dickinson and Company’s self-administered therapies with a ready-to-use, scalable platform.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis’ robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
-
Canopy raises $22 million for healthcare safety platform
The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.
-
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
-
Endometriosis study uncovers molecular subgroups to guide trials
Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.
-
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
-
Secura Bio’s Copiktra PTCL data shines at ASH 2025
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.